An official website of the United States government
Home
Name
Erlotinib
Alternate Names
CP-358774
Erlotinib HCl
OSI-774
Tarceva
Abbreviations
None
Category
Chemotherapy
Subcategory
Cytostatic agent--tyrosine kinase inhibitor
EGF inhibitor
NSC Number
718781
Primary Site
Breast
Non-small cell lung cancer (NSCLC)
cervical
colorectal
gastric
head & neck
other cancer
ovarian
pancreatic
Histology
None
Remarks
October 18, 2016 FDA modified the indication for erlotinib (TARCEVA) for treatment of non-small cell lung cancer (NSCLC) to limit use to patients whose tumors have specific epidermal growth factor receptor (EGFR) mutations.
July 2013 UPDATE: Tarceva received FDA approval as first-line treatment of metastatic non-small cell lung cancer (NSCLC) patients whose tumors have epidermal growth factor receptor (EGFR) mutations. Prior to July 2013, tarceva was approved for use in patients who had failed previous chemotherapy regimens.
FDA approved for pancreas 2005, NSCLC 2004; Phase II (ovarian) Phase III (breast, head & neck)
Tyrosine kinase inhibitor. Epidermal growth factor inhibitor.
July 2013 UPDATE: Tarceva received FDA approval as first-line treatment of metastatic non-small cell lung cancer (NSCLC) patients whose tumors have epidermal growth factor receptor (EGFR) mutations. Prior to July 2013, tarceva was approved for use in patients who had failed previous chemotherapy regimens.
FDA approved for pancreas 2005, NSCLC 2004; Phase II (ovarian) Phase III (breast, head & neck)
Tyrosine kinase inhibitor. Epidermal growth factor inhibitor.
Coding
This drug should be coded
